Edition:
India

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

47.33USD
11:56pm IST
Change (% chg)

$1.80 (+3.96%)
Prev Close
$45.53
Open
$46.45
Day's High
$47.62
Day's Low
$44.70
Volume
130,425
Avg. Vol
263,279
52-wk High
$66.16
52-wk Low
$8.51

Select another date:

Fri, Aug 21 2020

Photo

Arcturus CEO says in talks with a dozen countries for COVID-19 vaccine supply deals

Arcturus Therapeutics Holdings Inc is in discussions with about a dozen countries for supply deals of its coronavirus vaccine that is currently in early human testing, the company's chief executive officer told Reuters on Thursday.

Arcturus CEO says in talks with a dozen countries for COVID-19 vaccine supply deals

Aug 20 Arcturus Therapeutics Holdings Inc is in discussions with about a dozen countries for supply deals of its coronavirus vaccine that is currently in early human testing, the company's chief executive officer told Reuters on Thursday.

Arcturus Therapeutics begins human trials of potential COVID-19 vaccine

Arcturus Therapeutics Holdings Inc said on Tuesday the first group of participants had been dosed in an early-stage trial testing its COVID-19 vaccine candidate and that results from the trial were expected in the fourth quarter.

UPDATE 1-Arcturus Therapeutics begins human trials of potential COVID-19 vaccine

Aug 11 Arcturus Therapeutics Holdings Inc said on Tuesday the first group of participants had been dosed in an early-stage trial testing its COVID-19 vaccine candidate and that results from the trial were expected in the fourth quarter.

BRIEF-Arcturus Therapeutics To Be Added To Russell 2000® Index

* ARCTURUS THERAPEUTICS TO BE ADDED TO RUSSELL 2000® INDEX Source text for Eikon: Further company coverage:

Singapore scientists to start human trials of COVID-19 vaccine in August

SINGAPORE Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.

Singapore scientists to start human trials of COVID-19 vaccine in August

SINGAPORE Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.

BRIEF-Arcturus Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Study Of ARCT-810

* ARCTURUS THERAPEUTICS ANNOUNCES FIRST HEALTHY VOLUNTEER DOSED IN PHASE 1 STUDY OF ARCT-810 FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Arcturus Reports Positive Preclinical Data For Covid-19 Vaccine Candidate (April 27)

(Corrects company name in second bullet) Arcturus Therapeutics Holdings Inc:

BRIEF-Arcturus Therapeutics Announces Proposed Public Offering Of Common Stock

* ARCTURUS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Select another date: